...
首页> 外文期刊>Diabetes care >Glargine and cancer: Can we now suggest closure?
【24h】

Glargine and cancer: Can we now suggest closure?

机译:甘精胰岛素和癌症:我们现在可以建议停用吗?

获取原文
获取原文并翻译 | 示例
           

摘要

The two publications on the pharma-cokinetics of insulin glargine in individuals with type 1 and type 2 diabetes in this issue of Diabetes Care (1,2) provide additional explanatory evidence in support of the definitive findings in the Outcome Reduction with Initial Glargine Intervention (ORIGIN) study in which exposure to insulin glargine for a median duration of 6.2 years did not increase the risk of any cancer (hazard ratio 1.00 [95% CI 0.88-1.13]) or death from cancer (0.94 [0.77-1.15]) (3).
机译:在本期《糖尿病护理》(1,2)中,关于甘精胰岛素在1型和2型糖尿病患者中药代动力学的两篇出版物提供了额外的解释性证据,以支持初步甘精胰岛素干预减少结局的明确发现( (ORIGIN)研究表明,接受甘精胰岛素的中位时间为6.2年,并未增加任何癌症的风险(危险比1.00 [95%CI 0.88-1.13])或癌症死亡的风险(0.94 [0.77-1.15])( 3)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号